(Q26863624)

diffuse large B-cell lymphoma

main subject

3 references

3 April 2019

2 October 2019

18 November 2019

1 reference

2 October 2019

1 reference

18 November 2019

positron emission tomography

1 reference

Fluorodeoxyglucose Positron Emission Tomography

23 November 2020

1 reference

Monica Coughlan

1

1 reference

Rebecca Elstrom

series ordinal

2

1 reference

language of work or name

1 reference

29 November 2014

5 references

3 April 2019

2 October 2019

18 November 2019

23 November 2020

4 references

2 October 2019

18 November 2019

23 November 2020

14

1 reference

page(s)

34

1 reference

Creative Commons Attribution

copyright license

4 references

3 April 2019

2 October 2019

18 November 2019

23 November 2020

0 references

on focus list of Wikimedia project

ScienceSource

0 references

cites work

Links between metabolism and cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4264252

Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4264252

Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group.

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4264252

Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4264252

[18F]fluorodeoxyglucose positron emission tomography predicts survival after chemoimmunotherapy for primary mediastinal large B-cell lymphoma: results of the International Extranodal Lymphoma Study Group IELSG-26 Study.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4264252

FDG PET/CT for the detection of bone marrow involvement in diffuse large B-cell lymphoma: systematic review and meta-analysis

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4264252

Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4264252

Interim PET-CT in the management of diffuse large B-cell lymphoma

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4264252

Fundamentals of PET and PET/CT imaging

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4264252

18F-FDG PET/CT for early response assessment in diffuse large B-cell lymphoma: poor predictive value of international harmonization project interpretation

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4264252

Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4264252

Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in Advanced-stage diffuse large B-Cell lymphoma

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4264252

Interim positron emission tomography scans in diffuse large B-cell lymphoma: an independent expert nuclear medicine evaluation of the Eastern Cooperative Oncology Group E3404 study

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4264252

High incidence of false-positive PET scans in patients with aggressive non-Hodgkin's lymphoma treated with rituximab-containing regimens

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4264252

The role of FDG-PET scans in patients with lymphoma

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4264252

PET/CT: form and function

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4264252

Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4264252

PET and PET/CT imaging: what clinicians need to know

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4264252

Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4264252

18F-fluoro-deoxyglucose positron emission tomography for post-treatment evaluation of malignant lymphoma: a systematic review.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4264252

FDG-PET scanning for detection and staging of extranodal marginal zone lymphomas of the MALT type: a report of 42 cases

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4264252

Clinical role of FDG PET in evaluation of cancer patients

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4264252

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4264252

Report on the 4th International Workshop on Positron Emission Tomography in Lymphoma held in Menton, France, 3-5 October 2012.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4264252

FDG accumulation and tumor biology

31 May 2018

1 reference

https://api.crossref.org/works/10.1186%2FS40644-014-0034-9

The Netherlands protocol for standardisation and quantification of FDG whole body PET studies in multi-centre trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS40644-014-0034-9

Interim positron emission tomography scan in multi-center studies: optimization of visual and quantitative assessments

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS40644-014-0034-9

Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS40644-014-0034-9

Standardization of image quality across multiple centers by optimization of acquisition and reconstruction parameters with interim FDG-PET/CT for evaluating diffuse large B cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS40644-014-0034-9

Utility of FDG-PET scanning in lymphoma by WHO classification

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS40644-014-0034-9

Positron emission tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG) for the staging of low-grade non-Hodgkin's lymphoma (NHL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS40644-014-0034-9

Bone marrow 18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography cannot replace bone marrow biopsy in diffuse large B-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS40644-014-0034-9

In newly diagnosed diffuse large B-cell lymphoma, determination of bone marrow involvement with 18F-FDG PET/CT provides better diagnostic performance and prognostic stratification than does biopsy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS40644-014-0034-9

PET-CT staging of DLBCL accurately identifies and provides new insight into the clinical significance of bone marrow involvement.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS40644-014-0034-9

Revised response criteria for malignant lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS40644-014-0034-9

Report on the First International Workshop on Interim-PET-Scan in Lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS40644-014-0034-9

Reproducibility of standardized uptake value measurements determined by 18F-FDG PET in malignant tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS40644-014-0034-9

Marked, homogeneous, and early [18F]fluorodeoxyglucose-positron emission tomography responses to vemurafenib in BRAF-mutant advanced melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS40644-014-0034-9

Predictive and prognostic value of metabolic tumour volume and total lesion glycolysis in solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS40644-014-0034-9

Early restaging positron emission tomography with ( 18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS40644-014-0034-9

Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS40644-014-0034-9

Prognostic value of interim 18F-FDG PET in patients with diffuse large B-Cell lymphoma: SUV-based assessment at 4 cycles of chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS40644-014-0034-9

Prognostic significance of interim ¹⁸F-FDG PET/CT after three or four cycles of R-CHOP chemotherapy in the treatment of diffuse large B-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS40644-014-0034-9

Midtreatment 18F-fluorodeoxyglucose positron-emission tomography in aggressive non-Hodgkin lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS40644-014-0034-9

Limited role of interim PET/CT in patients with diffuse large B-cell lymphoma treated with R-CHOP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS40644-014-0034-9

Interim 18-FDG-PET/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS40644-014-0034-9

Interim [18F]fluorodeoxyglucose positron emission tomography scan in diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy plus rituximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS40644-014-0034-9

SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS40644-014-0034-9

Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS40644-014-0034-9

Comparison of various criteria in interpreting end of therapy F-18 labeled fluorodeoxyglucose positron emission tomography/computed tomography in patients with aggressive non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS40644-014-0034-9

Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS40644-014-0034-9

A unifying approach for surrogate marker validation based on Prentice's criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS40644-014-0034-9

18F-FDG PET as a candidate for "qualified biomarker": functional assessment of treatment response in oncology.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4264252

18F-FDG PET for evaluation of bone marrow infiltration in staging of lymphoma: a meta-analysis.

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4264252

PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease.

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4264252

Procedure guideline for tumor imaging with 18F-FDG PET/CT 1.0.

28 November 2018

1 reference

https://pubmed.ncbi.nlm.nih.gov/25608713

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Interim PET/CT-based prognostic model for the treatment of diffuse large B cell lymphoma in the post-rituximab era

1 reference

https://pubmed.ncbi.nlm.nih.gov/25608713

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Persistent tumor 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin's lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/25608713

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1186/S40644-014-0034-9

1 reference

Dimensions Publication ID

1039143930

0 references

1 reference

1 reference

PubMed publication ID

25608713

1 reference